Loading
Pharmacology and Obesity Treatment / Metabolism, Diabetes, and Cancer / Diabetes Treatment and Management · Journal article
Current Medical Research and Opinion · September 3, 2026
A consensus or society position rather than new primary data.
This narrative review examines pharmacological strategies for type 2 diabetes prevention in individuals with prediabetes and/or obesity. Metformin has the most established long-term prevention evidence; GLP-1 agonists and tirzepatide offer weight loss and potential cardiometabolic benefits; SGLT2 inhibitors show cardiovascular and renal protection but insufficient evidence for diabetes prevention alone. Lifestyle intervention and weight management remain foundational, with drug selection individualised by metabolic risk and comorbidities.
Narrative review. Individuals with prediabetes and/or obesity at high risk of type 2 diabetes progression, without established diabetes.. Intervention: Pharmacological prevention strategies: metformin, SGLT2 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 agonist tirzepatide, and emerging triple receptor agonists, positioned within lifestyle and weight management..
Metformin remains the glucose-lowering agent with the most established long-term evidence for diabetes prevention in selected high-risk individuals with prediabetes, acting through AMPK-dependent and AMPK-independent hepatic and intestinal mechanisms. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonist tirzepatide produce clinically meaningful weight loss and broader cardiometabolic benefits that may reduce progression to T2DM in high-risk individuals. SGLT2 inhibitors provide substantial cardiovascular and renal protection, although current evidence is insufficient to support their routine use solely for T2DM prevention.
Review does not report adverse event profiles, cost-effectiveness, or long-term adherence data for prevention strategies. Lifestyle intervention and sustained weight management remain the foundation of T2DM prevention, with pharmacological strategies selected according to individual metabolic risk, obesity-related treatment indications, comorbidities, and strength of evidence.
This review provides a framework for selecting preventive pharmacotherapy in at-risk individuals, establishing metformin as the standard of evidence-based prevention, and contextualizing newer agents (GLP-1 agonists, tirzepatide) as adjuncts to lifestyle intervention based on individual cardiometabolic risk profiles and comorbidities.
A narrative review synthesizing evidence on pharmacological strategies for type 2 diabetes prevention in obese individuals, grading existing agents by strength of preventive evidence and positioning incretin agonists within the prevention landscape.
As stated by the source record.
Quoted from the source exactly as published.
This review provides a framework for selecting preventive pharmacotherapy in at-risk individuals, establishing metformin as the standard of evidence-based prevention, and contextualizing newer agents (GLP-1 agonists, tirzepatide) as adjuncts to lifestyle intervention based on individual cardiometabolic risk profiles and comorbidities.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Type 2 diabetes mellitus (T2DM) represents one of the most significant metabolic challenges of the modern era, with more than 828 million people worldwide living with diabetes. Obesity and insulin resistance are major modifiable contributors to T2DM risk and progression, although the disease is heterogeneous and arises from complex interactions among β-cell dysfunction, hepatic glucose dysregulation, adipose-tissue dysfunction, altered incretin biology, chronic low-grade inflammation, and genetic susceptibility. In individuals with obesity and insulin resistance, progression through prediabetes to overt hyperglycaemia represents an important, although not universal, disease trajectory and provides a clinically relevant window for preventive intervention. This review examines pharmacological strategies relevant to T2DM prevention in individuals without established diabetes who have prediabetes and/or obesity associated with a high risk of progression to T2DM, with particular emphasis on incretin-based obesity pharmacotherapy. Metformin remains the glucose-lowering agent with the most established long-term evidence for diabetes prevention in selected high-risk individuals with prediabetes, acting through multiple hepatic and intestinal mechanisms involving both AMPK-dependent and AMPK-independent pathways. Other established antihyperglycaemic drug classes are discussed primarily to distinguish therapies with evidence for delaying progression to diabetes from agents whose principal role remains the treatment of established T2DM. SGLT2 inhibitors provide substantial cardiovascular and renal protection, although current evidence is insufficient to support their routine use solely for T2DM prevention. GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide have substantially advanced obesity pharmacotherapy, producing clinically meaningful weight loss and broader cardiometabolic benefits that may reduce progression to T2DM in high-risk individuals.Next-generation incretin-based therapies, including triple receptor agonists, may further expand therapeutic options but remain an evolving area of investigation. Lifestyle intervention and sustained weight management remain the foundation of T2DM prevention, with pharmacological strategies selected according to individual metabolic risk, obesity-related treatment indications, comorbidities, and the strength of evidence supporting diabetes prevention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.